Free Article Directory Swaziland: Differin

Differin is a brand name of adapalene topical, approved by the FDA in the following formulation(s):

DIFFERIN (adapalene - cream; topical)

Manufacturer: GALDERMA LABS LP

Approval date: May 26, 2000

Strength(s): 0.1% ^[RLD]^[AB]

DIFFERIN (adapalene - gel; topical)

Manufacturer: GALDERMA LABS LP

Approval date: May 31, 1996

Strength(s): 0.1% ^[RLD]^[AB]

Manufacturer: GALDERMA LABS LP

Approval date: June 19, 2007

Strength(s): 0.3% ^[RLD]

DIFFERIN (adapalene - lotion; topical)

Manufacturer: GALDERMA R AND D

Approval date: March 17, 2010

Strength(s): 0.1% ^[RLD]

Has a generic version of Differin been approved?

A generic version of Differin has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Differin and have been approved by the FDA:

adapalene cream; topical

Manufacturer: FOUGERA PHARMS

Approval date: June 30, 2010

Strength(s): 0.1% ^[AB]

adapalene gel; topical

Manufacturer: GLENMARK GENERICS

Approval date: July 1, 2010

Strength(s): 0.1% ^[AB]

Manufacturer: PLIVA HRVATSKA DOO

Approval date: June 2, 2010

Strength(s): 0.1% ^[AB]

Note: No generic formulation of the following product is available.

adapalene - lotion; topical

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Differin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,579,377
Issued: August 25, 2009
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefore, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- February 23, 2025
  ✓
  Patent use: TOPICAL TREATMENT OF ACNE VULGARIS

Pharmaceutical compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,737,181
Issued: June 15, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Patent expiration dates:
- August 29, 2024
  ✓
  Drug product

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoic acid for the treatment of dermatological disorders
Patent 7,834,060
Issued: November 16, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- March 12, 2023
  ✓
  Patent use: TREATMENT OF ACNE

Administration of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid for the treatment of dermatological disorders
Patent 7,838,558
Issued: November 23, 2010
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development S.N.C.
Dermatological disorders having an inflammatory or proliferative component are treated with pharmaceutical compositions containing on the order of 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously topically applicable gels, creams or lotions.
Patent expiration dates:
- March 12, 2023
  ✓
  Drug product

Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid
Patent 7,868,044
Issued: January 11, 2011
Inventor(s): Graeber; Michael & Czernielewski; Janusz
Assignee(s): Galderma Research & Development
Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.
Patent expiration dates:
- March 12, 2023
  ✓
  Patent use: TREATMENT OF ACNE

Cosmetic/dermatological compositions comprising naphthoic acid compounds and polyurethane polymers
Patent 7,998,467
Issued: August 16, 2011
Inventor(s): Mallard; Claire & Ferrara; Eve
Assignee(s): Galderma Research & Development
Cosmetic/dermatological compositions for topical application and useful for the treatment, e.g., of acne, contain, formulated into a physiologically acceptable medium, at least one naphthoic acid compound and at least one polyurethane polymer or derivative thereof, the at least one naphthoic acid compound being dispersed therein.
Patent expiration dates:
- May 31, 2028
  ✓
  Patent use: TREATMENT OF ACNE
  ✓
  Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- March 17, 2013 - NEW DOSAGE FORM

Free Article Directory Swaziland

Wednesday, September 21, 2016

Differin